Logo Image

Authors

Vinay Gupta, MD
Latest Article

Novel Proteasome Inhibitors for Multiple Myeloma

The recent approval of the second-generation proteasome inhibitor carfilzomib by the FDA comes nine years after the initial approval of bortezomib, the first-in-class drug of its type.

Virginia Powers
Latest Article

An Expert's Overview of CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast Cancer

Inhibition of CDK4/6 results in improvements in progression-free survival in women with estrogen receptor ER-positive HER2-negative metastatic breast cancer whether it is endocrine sensitive or resistant.

Virginia Powers, PhD
Latest Article

Acalabrutinib Shows High Response, Prolonged Survival in Ibrutinib-Intolerant R/R CLL

Bruton tyrosine kinase inhibitor acalabrutinib demonstrated a high rate of response, prolonged survival, and high tolerability in patients with chronic lymphocytic leukemia who demonstrated intolerance to ibrutinib. Findings were presented at the 15th International Conference on Malignant Lymphoma.

Vivek N. Patel, MD
Latest Article

A Phase II Trial of Cetuximab and Docetaxel With Radiation for Head and Neck Cancer

The use of low-dose radiotherapy may offer transient benefits; nonetheless the potential for palliative care exists.

W. Todd Penberthy
Latest Article

Sub-Centimeter Thyroid Nodule Size May Not Offer Good Prognostic Indicator for Biopsy

The rising overall risk of all sizes of malignant thyroid cancer has made clinicians question whether or not sub-centimeter thyroid nodules should also be biopsied.

W. Todd Penberthy, PhD
Latest Article

PD-L1 Strongly Correlates With Papillary Thyroid Cancer Aggressiveness

Investigators at the Mount Sinai School of Medicine, Toronto, Canada, have been working on a potential correlation for aggressiveness and/or disease-free survival in thyroid cancer patients.

Wade T. Iams, MD
Latest Article

RET Rearrangements in Non-Small Cell Lung Cancer

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer. These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468.

Walter Alexander
Latest Article

Third-Line Eribulin Effective, Safe in Metastatic Breast Cancer

Among patients with HER2-negative stage IIIb/IV breast cancer who have progressed after a taxane or anthracycline therapy, a multicenter single-arm study of third-line eribulin demonstrated both safety and efficacy.

Walter J. Curran Jr, MD
Walter J. Curran, Jr., MD, FACR
Latest Article

Radiation Therapy Dose for the Treatment of Patients With Lung Cancer

Walter J. Curran, Jr., MD, FACR, associate vice president of cancer, Woodruff Health Sciences Center, executive director, Winship Cancer Institute, Lawrence W. Davis Chair of Radiation Oncology, Emory University, discusses radiation therapy dose for the treatment of patients with lung cancer.

Wayne Kuznar
Latest Article

BGB-11417 +/- Zanubrutinib Demonstrates Early Efficacy Signals in CLL/SLL

Phase 1 clinical trial data shows that BGB-11417 may induce response and lead to minimal residual disease negativity in patients with chronic lymphocytic leukemia.

Wayne Kuzner
Latest Article

PSMA-Directed Therapies and Diagnostics Expand Their Scope in Prostate Cancer

With the emergence of therapies that target PSMA, a cell surface transmembrane protein that is overexpressed in most prostate cancer cells, particularly in castration-resistant disease, the ability to detect and treat the disease has been transformed.

Wells Messersmith, MD
Will Pass, DVM
Latest Article

FDA Issues Draft Guidance to Broaden Clinical Trial Inclusion

The FDA recently released 5 new draft guidance documents that promote broader patient eligibility for cancer clinical trials. The policies encourage inclusion of certain individuals who were previously disqualified due to medical conditions or biological factors, including brain metastases, organ dysfunction, prior or concurrent malignancies, chronic infections, and age.

William M. Grady, MD
William Oh, MD
Latest Article

Incorporating Biomarker Testing in Community Cancer Clinics: A Real-World Pilot Study

Although there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.

William T. DeRosa, DO
William Wierda, MD, PhD
Wilson I. Gonsalves, MD
Xiaoliang Wu, MD
Latest Article

Current Role of MET Inhibitors in Cancer Therapy

Emerging discoveries of MET chromosomal fusions provide additional promise as therapeutic genomic targets in MET cancer therapy and would need to be tested vigorously.

Yujie Zhao, MD, PhD
Latest Article

Levantinib in the Management of Differentiated Thyroid Cancer

Therapy that targets angiogenesis has been extensively investigated in differentiated thyroid cancer (DTC) and has demonstrated significant antitumor activity.

Zachary S. Buchwald, MD, PhD
Gina Mauro
Latest Article

Bruce Haffty, MD, and Mutlay Sayan, MD, on Radiation Oncology's Next Frontier and Mentorship

Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.

Nina Shah, MD

Nina Shah, MD, is a hematologist-oncologist at University of California, San Francisco who focuses on treating multiple myeloma.

Richard Payerchin
Latest Article

Nine Staff Management Essentials for Physicians

Discover essential strategies for physicians to enhance team management in medical practices, fostering efficiency and improving patient care.

Ian E. Krop, MD, PhD
Marielle Fares, PharmD, BCGP
Latest Article

Novel Delivery Systems, Unique Pairings Explored With Oncolytic Viruses

Oncoloytic viruses are an emerging class of cancer therapeutics that may provide a new strategy against malignant tumors.

Ashok Muthukrishnan, MD, MS
Ashok Muthukrishnan, MD, MS

Ashok Muthukrishnan, MD, MS, is the chief of Nuclear Medicine, and director of Theranostics in the Department of Radiology at the University of Pittsburgh Medical Center in Pittsburgh, PA.

Latest Article

Pluvicto Approval Launches Theranostics in Prostate Cancer

Ashok Muthukrishnan, MD, MS, addresses the recent FDA approval of lutetium 177Lu vipivotide tetraxetan and looks to the potential of radioimmunotheranostics on the horizon.

Niroshana Anandasabapathy, MD, PhD
Latest Article

Melanoma Monday: From Early Detection to Cutting-Edge Treatments

May 6, 2024, is Melanoma Monday. In this article, Niroshana Anandasabapathy, MD, PhD, explores how advancements in detection and treatment are improving the fight against melanoma.

Peter Hillmen, MBChB, PhD
Latest Article

Hillmen Analyzes Current and Upcoming Trials of BTK Inhibitors

During a Targeted Oncology Case-Based Peer Perspectives event, Peter Hillmen, MBChB, PhD, discussed the case of 61-year-old patient with diffuse infiltration by chronic leukocytic leukemia.